Mayinglong Pharmaceutical Group Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Youzhang Xia

Chief Executive Officer (CEO)

CN¥1.8m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

CEO

Youzhang Xia (45 yo)

no data

Permanencia

CN¥1,800,000

Compensación

Mr. Youzhang Xia serves as General Manager and Director at Mayinglong Pharmaceutical Group Co., Ltd. and served as its Deputy General Manager and Secretary of the Board.

Mayinglong Pharmaceutical Group Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Mayinglong Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 18, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.32 in 3Q 2023)

Mayinglong Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.21 in 2Q 2023)

Dividend increased to CN¥0.40

Now 21% overvalued after recent price rise

Mayinglong Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Mayinglong Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 18, 2024

Full year 2023 earnings released: EPS: CN¥1.03 (vs CN¥1.11 in FY 2022)

Mayinglong Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 20, 2024

Mayinglong Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024

Third quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.34 in 3Q 2022)

New major risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.31 in 2Q 2022)

Mayinglong Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 26, 2023

Full year 2022 earnings released: EPS: CN¥1.11 (vs CN¥1.08 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.26 in 3Q 2021)

Now 20% undervalued

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.32 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.32 (vs CN¥0.27 in 1Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.22 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.30 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.25 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.97 (vs CN¥0.84 in FY 2019)

Mayinglong Pharmaceutical Group Co., LTD. to Report Fiscal Year 2020 Results on Mar 26, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥19.37

Investor sentiment improved over the past week

New 90-day high: CN¥22.36

New 90-day low: CN¥20.67

Third quarter earnings released

Mayinglong Pharmaceutical Group Co., LTD. to Report Q3, 2020 Results on Oct 24, 2020

New 90-day low: CN¥20.92

Earnings released

Mayinglong Pharmaceutical Group Co., LTD. to Report First Half, 2020 Results on Aug 22, 2020

CEO

Permanencia

Compensación